Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 322-329

  Ranieri, Girolamo ^a   Mammì, Maria ^b   Donato Di Paola, Eugenio ^b   Russo, Emilio ^b   Gallelli, Luca ^b   Citraro, Rita ^b   Gadaleta, Cosmo Damiano ^a   Marech, Ilaria ^a   Ammendola, Michele ^b   De Sarro, Giovambattista ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Angiogenesis; Pazopanib; Soft tissue sarcoma; Targeted therapy; Tyrosine kinase inhibitor (TKI); Vascular endothelial growth factor (VEGF)

Indexed keywords

DOXORUBICIN; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADIPOCYTIC SARCOMA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; DECREASED APPETITE; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FIBROHISTIOCYTIC SARCOMA; FIBROSARCOMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; REVIEW; RHABDOMYOSARCOMA; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SYNOVIAL SARCOMA; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR TUMOR; VOMITING;

ANGIOGENESIS; PAZOPANIB; SOFT TISSUE SARCOMA; TARGETED THERAPY; TYROSINE KINASE INHIBITOR (TKI); VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SARCOMA; SIGNAL TRANSDUCTION; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84892505431     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.012     Document Type: Review

References (49)

1. Skubitz K.M., D'Adamo D.R. Sarcoma. Mayo Clinic Proceedings 2007, 82:1409-1432.
2. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nature Reviews Cancer 2003, 3:685-694.
3. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). Journal of Clinical Oncology 2009, 27(19):3126-3132.
4. Brennan M., Singer S., Maki R., O'Sullivan B. Sarcomas of the soft tissue and bone. Cancer: Principles and Practice of Oncology 2004, vol. 2. Lippincott Williams and Wilkins, Philadelphia. 7th edition.
5. Clark M.A., Fischer C., Judson I., Thomas J.M. Soft-tissue sarcoma in adults. New England of Journal Medicine 2005, 353:701-711.
6. Van Oosterom A.T., Verweij J. New drugs for the treatment of sarcoma. Hematology/Oncology Clinics of North America 1995, 9:909-925.
7. Penel N., Van Glabbeke M., Marreaud S., Ouali M., Blay J.Y., Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Annals of Oncology 2011, 22(6):1266-1272.
8. Van Glabbeke M., Verweij J., Judson I., Nielsen O.S. Progression-free rate as the primary endpoint for phase II study in soft tissue sarcoma. European Journal of Cancer 2002, 38:543-549.
9. Folkman J., Shing Y. Angiogenesis. Journal of Biological Chemistry 1992, 10931-10934.
10. Breier G. Angiogenesis in embryonic development-a review. Placenta 2000, 21(Suppl A):S11-S15.
11. Iruela-Arispe M.L., Dvorak H.F. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thrombosis and Haemostasis 1997, 78:672-677.
12. Daniel T.O., Abrahamson D. Endothelial signal integration in vascular assembly. Annual Review of Physiology 2000, 62:649-671.
13. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Experimental Cell Research 1999, 253:117-130.
14. Nugent M., Iozzo R.V. Fibroblast growth factor-2. The International Journal of Biochemistry & Cell Biology 2000, 32:115-120.
15. Gadaleta C.D., Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Critical Reviews in Oncology/Hematology 2011, 80:40-53.
16. Ranieri G., Ammendola M., Patruno R., et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. International Journal of Oncology 2009, 35:115-120.
17. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. The FASEB Journal 1996, 10:1183-1191.
18. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
19. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
20. Ranieri G., Pantaleo M., Piccinno M., et al. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Critical Reviews in Oncology/Hematology 2013, doi:pii:S1040-8428(13)00103-0; Jun 12 [Epub ahead of print].
21. Ranieri G., Gadaleta C.D., Patruno R., et al. A model of study for human cancer: spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical Reviews in Oncology/Hematology 2013, 5-6. doi:pii:S1040-8428(13)00065-6; Apr 2.
22. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Annals of Surgery 1972, 175:409-416.
23. Ranieri G., Grammatica L., Patruno R., et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. Journal of Cellular and Molecular Medicine 2007, 2:362-368.
24. Ranieri G., Labriola A., Achille G., et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. International Journal of Oncology 2002, 6:1317-1323.
25. Lammli J., Fan M., Rosenthal H.G., et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. International Orthopaedics 2012, 36(11):2307-2313.
26. Potti A., Ganti A.K., Foster H., et al. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Research 2004, 24(1):333-337.
27. Potti A., Ganti A.K., Tendulkar K., et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. Journal of Cancer Research and Clinical Oncology 2004, 130(1):52-56.
28. Graeven U., Andre N., Achilles E., Zornig C., Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. Journal of Cancer Research and Clinical Oncology 1999, 125(10):577-581.
29. Chao C., Al-Saleem T., Brooks J.J., Rogatko A., Kraybill W.G., Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Annals of Surgical Oncology 2001, 8(3):260-267.
30. Iyoda A., Hiroshima K., Baba M., Fujisawa T., Yusa T., Ohwada H. Expression of vascular endothelial growth factor in thoracic sarcomas. The Annals of Thoracic Surgery 2001, 5:1635-1639.
31. Comandone A., Bretti S., Bertetto O., Oliva C., Bergnolo P., Bumma C. Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas. Anticancer Research 2000, 20(3B):2077-2080.
32. Avdalyan A., Bobrov I., Klimachev V., Lazarev A. Prognostic value of microvessel density in tumor and peritumoral area as evaluated by cd31 protein expression and argyrophilic nucleolar organizer region count in endothelial cells in uterine leiomyosarcoma. Sarcoma 2012, 2012:594512.
33. Gaumann A.K., Schermutzki G., Mentzel T., Kirkpatrick C.J., Kriegsmann J.B., Konerding M.A. Microvessel density and VEGF/VEGF receptor status and their role in sarcomas of the pulmonary artery. Oncology Reports 2008, 19(2):309-318.
34. Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Current Medicinal Chemistry 2006, 13:1845-1857.
35. Ranieri G. Hot topic: targeting tumor angiogenesis: an update. Current Medicinal Chemistry 2012, 19:937.
36. Ranieri G., Gadaleta-Caldarola G., Goffredo V., et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Current Medicinal Chemistry 2012, 19:938-944.
37. Hamberg P., Verweij J., Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. The Oncologist 2010, 15(6):539-547.
38. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics 2007, 6:2012-2021.
39. Podar K., Tonon G., Sattler M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Science of the United States of America 2006, 103:19478-19483.
40. Hurwitz H.I., Dowlat A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clinical Cancer Research 2009, 15:4220-4227.
41. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 2010, 28:1061-1068.
42. Hutson T.E., Davis I.D., Machiels J.P., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2010, 28:475-480.
43. Yau C.C., Chen P.J., Chan P., et al. Phase I study of pazopanib in hepatocellular carcinoma: evaluation of clinical activity, pharmacokinetics and dynamic contrast enhanced MRI (DCE MRI). European Journal of Cancer 2009, 7(Suppl 2):122.
44. Altorki N., Heymach J., Guarino M., et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study. Annals of Oncology 2008, 19(Suppl 8):89.
45. Friedlander M., Hancock K.C., Benigno B., et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: final results of a phase II study. Annals of Oncology 2008, 19(Suppl 8):211.
46. Prince H.M., Hönemann, Spencer A., et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009, 113:4819-4820.
47. National Cancer Institute. FDA Approval for Pazopanib Hydrochloride. (accessed 10.05.12). http://www.cancer.gov/cancertopics/druginfo/fda-pazopanibhydrochloride.
48. Van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379(May (9829)):1879-1886.
49. FDA approves Votrient for advanced soft tissue sarcoma. http://www.fda.gov/.